Dr. Eduardo Santos, MD, FACP, FCCP, provides and overview of immunotherapy-based treatment strategies for NSCLC in the neoadjuvant and perioperative setting.
The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer.